- Home
- / Yongtai Biopharmaceutical
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Yongtai Biopharmaceutical financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$1.8
2024-10-29
Market Capitalization
$1 B
2024-10-29
CreditSafe Score
?
Score changed on Jun 10, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| CNY | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross profit | 5.0M | 2.4M | 2.4M | 10.2M | 5.9M | 7.5M | 32.7M | 20.0M |
| Operating expense total | 42.5M | 109.1M | 371.5M | 322.3M | 241.1M | 175.1M | 139.8M | 119.5M |
| Depreciation and amortization | 4.5M | 12.7M | 13.8M | 21.6M | 46.6M | 55.9M | 61.7M | 55.6M |
| EBITDA | (37.5M) | (106.6M) | (369.2M) | (312.1M) | (235.2M) | (167.6M) | (107.1M) | (99.5M) |
| EBIT | (42.3M) | (115.6M) | (399.9M) | (333.4M) | (283.9M) | (223.1M) | (214.4M) | (155.7M) |
| Interest income | 234.0K | 440.0K | 3.7M | 7.6M | 3.2M | 3.0M | 1.1M | 532.0K |
| Interest expense | 1.1M | 2.1M | 2.4M | 3.7M | 6.1M | 8.5M | 7.5M | 6.8M |
| Pre tax profit | (34.9M) | (109.1M) | (439.1M) | (354.6M) | (321.1M) | (335.5M) | (186.4M) | (230.9M) |
| Income tax expense | 926.0K | |||||||
| Net Income | (34.9M) | (109.1M) | (439.1M) | (354.6M) | (321.1M) | (335.5M) | (187.3M) | (230.9M) |